Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Ariad celebrates drug approval with a $310mm public offering

Executive Summary

Cancer therapeutics developer Ariad Pharmaceuticals Inc. netted $310mm through the public sale of 16.5mm common shares (including partial exercise of the overallotment) at $19.60. The company will use some of the proceeds to fund marketing and manufacturing activities for Iclusig (ponatinib), which just last month received accelerated approval from the FDA to treat adults with chronic, accelerated, or blast phase chronic myeloid leukemia that is resistant to prior tyrosine kinase inhibitor (TKI) therapies, or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia resistant to TKIs.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register